Sinco Pharmaceuticals Holdings Full Year 2023 Earnings: EPS: CN¥0.021 (vs CN¥0.034 in FY 2022)

Sinco Pharmaceuticals Holdings (HKG:6833) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥2.54b (up 12% from FY 2022).
• Net income: CN¥42.4m (down 39% from FY 2022).
• Profit margin: 1.7% (down from 3.1% in FY 2022). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.021 (down from CN¥0.034 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

The primary driver behind last 12 months revenue was the Sale of Imported Pharmaceutical Products segment contributing a total revenue of CN¥2.51b (99% of total revenue). Notably, cost of sales worth CN¥2.22b amounted to 87% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥113.1m (40% of total expenses). Explore how 6833's revenue and expenses shape its earnings.

Sinco Pharmaceuticals Holdings' share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Sinco Pharmaceuticals Holdings that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.